Effect of Intravenous Tranexamic Acid in Reducing in Spinal Surgeries

Evaluation of the Effect of Intravenous Tranexamic Acid in Reducing the Amount of Intraoperative Bleeding in Major Lumbar Spinal Surgeries with Instruments (A Randomized Double-blind Clinical Trial Study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230519058227N1

Enrollment

Registered

2023-07-04

Start date

2023-08-11

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Far lateral lumbar disc herniation. Condition 2: Lumbar spinal stenosis. Condition 3: Spondylolisthesis. Condition 4: Scoliosis. Condition 5: Lordosis. Condition 6: Extensive fracture of the lumbar vertebrae.

Interventions

Intervention 1: Intervention group: In the intervention group (group A), 30 minutes immediately before the skin incision,10 _ 15 mg/kg of intravenous Tranexamic acid as a loading dose (do not exceed t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient with far lateral lumbar disc herniation who requires instrumentation. A patient with lumbar spinal stenosis who requires instrumentation. A patient with Spondylolisthesis who requires instrumentation. A patient with Scoliosis who requires instrumentation. A patient with Lordosis who requires instrumentation. A patient has a extensive fracture of the lumbar vertebrae who requires instrumentation.

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Patients taking Anticoagulant Drugs. People with Congenital Coagulopathy. Patients who have a history of any type of Cerebral Hemorrhage such as SAH, ICH, SDH, EDH, IVH. Patients who have a history of Anaphylactic Reaction. Women who are pregnant. Patients who have a history of DVT and PTE. Patients who have a history of Chronic Renal Failure (Cr-baseline > 1.36 mg/dl). Patients with Chronic Liver Disease. Patients who have Platelets 1.5. Patients who have PT > 14. Patients who have PTT > 35.

Design outcomes

Primary

Measure	Time frame
Bleeding volume during operation. Timepoint: During operation. Method of measurement: By collecting the amount of blood in the suction and subtracting its amount from the amount of serum that was used in the washing place (the amount of serum used is noted) and counting the number of blood cells approximately.;The volume of blood collected daily in the hemovac drain after the operation. Timepoint: After installing the Hamovac drain on a daily basis. Method of measurement: The amount of blood collected in the Hemovac drain is charted daily in coordination with the surgeon.	—

Measure

Time frame

Bleeding volume during operation. Timepoint: During operation. Method of measurement: By collecting the amount of blood in the suction and subtracting its amount from the amount of serum that was used in the washing place (the amount of serum used is noted) and counting the number of blood cells approximately.;The volume of blood collected daily in the hemovac drain after the operation. Timepoint: After installing the Hamovac drain on a daily basis. Method of measurement: The amount of blood collected in the Hemovac drain is charted daily in coordination with the surgeon.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNima Bagheri

Karaj University of Medical Sciences

nima1376nba@yahoo.com+98 26 3428 7339

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026